11-tetradecenyl acetate: RN given refers to cpd with unspecified isomeric designation
ID Source | ID |
---|---|
PubMed CID | 5367650 |
CHEMBL ID | 3182789 |
CHEBI ID | 179817 |
SCHEMBL ID | 434571 |
MeSH ID | M0058780 |
Synonym |
---|
11e-tetradecenyl acetate |
26532-95-6 |
CHEBI:179817 |
[(e)-tetradec-11-enyl] acetate |
trans-11-tetradecen-1-yl acetate |
trans-11-tetradecenyl acetate |
(11e)-11-tetradecenyl acetate |
11-tetradecen-1-ol acetate |
trans-11-tetradecenyl acetate, ~97% |
NCGC00164396-01 |
(e)-11-tetradecenyl acetate |
einecs 251-401-4 |
(e)-11-tetradecen-1-ol acetate |
epa pesticide chemical code 129019 |
11-tetradecen-1-ol, acetate, (11e)- |
11-tetradecen-1-ol, acetate, (e)- |
epa pesticide chemical code 128980 |
(e)-tetradec-11-enyl acetate |
ai3-35943 |
11-tetradecenyl acetate |
NCGC00164396-02 |
grape berry moth pheromone |
11-tetradecen-1-ol, acetate |
LMFA07010285 |
NCGC00254953-01 |
cas-33189-72-9 |
dtxcid9015286 |
dtxsid1035286 , |
tox21_301051 |
unii-uxj691z784 |
11-tetradecenyl acetate, (11e)- |
33189-72-9 |
uxj691z784 , |
11-tetradecen-1-ol, 1-acetate, (11e)- |
SCHEMBL434571 |
trans-11-tetradecenol acetate |
tetradecen-1-ol acetate, (e)-11- |
YJINQJFQLQIYHX-UHFFFAOYSA-N |
trans-tetradec-11-en-1-yl acetate |
(11e)-tetradecen-1-yl acetate |
(11e)-tetradec-11-en-1-yl acetate |
trans-11-tetradecenylacetate |
(11e)-11-tetradecenyl acetate # |
YJINQJFQLQIYHX-SNAWJCMRSA-N |
CHEMBL3182789 |
e-11-tetradecenyl acetate |
mfcd00064462 |
E75959 |
Q27291316 |
(e)-11-tetradecen-1-yl acetate 100 microg/ml in acetonitrile |
BS-49280 |
CS-0160320 |
Excerpt | Relevance | Reference |
---|---|---|
"Medflies topically dosed with moth pheromone (E)-11-tetradecenyl acetate showed a no observed effect level (NOEL) of ~10 µg fly(-1) , with increasing toxicity from 30 to 100 µg fly(-1) ." | ( Mobile mating disruption of light-brown apple moths using pheromone-treated sterile Mediterranean fruit flies. Jang, EB; Lacey, I; Mitchell, VJ; Suckling, DM; Twidle, A; Wallace, AR; Woods, B, 2011) | 0.62 |
Class | Description |
---|---|
carboxylic ester | An ester of a carboxylic acid, R(1)C(=O)OR(2), where R(1) = H or organyl and R(2) = organyl. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Pathway | Proteins | Compounds |
---|---|---|
Spodoptera littoralis pheromone biosynthesis | 0 | 32 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 54.4827 | 0.0010 | 22.6508 | 76.6163 | AID1224838 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 24.5412 | 0.0008 | 17.5051 | 59.3239 | AID1159531 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 30.8956 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 38.5708 | 0.0003 | 23.4451 | 159.6830 | AID743066 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (6.25) | 18.7374 |
1990's | 2 (12.50) | 18.2507 |
2000's | 9 (56.25) | 29.6817 |
2010's | 3 (18.75) | 24.3611 |
2020's | 1 (6.25) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.74) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 17 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |